CDK8 as a therapeutic target for overall survival prediction in cervical squamous cell carcinoma (CESC).

IF 3.5 4区医学 Q3 ONCOLOGY Current cancer drug targets Pub Date : 2025-01-24 DOI:10.2174/0115680096332050241022102545

Feiting Xie, Qiugang Zhu, Shizhou Yang, Xiaofen Jin, Danqi Ruan, Lingfang Wang, Yang Li, Fang Ren, Xiaojing Chen

{"title":"CDK8 as a therapeutic target for overall survival prediction in cervical squamous cell carcinoma (CESC).","authors":"Feiting Xie, Qiugang Zhu, Shizhou Yang, Xiaofen Jin, Danqi Ruan, Lingfang Wang, Yang Li, Fang Ren, Xiaojing Chen","doi":"10.2174/0115680096332050241022102545","DOIUrl":null,"url":null,"abstract":"<p><p>Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth, and neurological functions, in conjunction with mediator complex subunits 12 (MED12), MED13, and cyclin C.Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth and neurological functions，in conjunction with mediator complex subunit 12 (MED12), MED13 and cyclin C. Studying the relationship between CDK8 and cervical squamous cell carcinoma (CESC) has significant clinical implications in diagnosis, treatment, and prognosis. We analyzed the relationship between CDK8 and poor prognosis of CESC. The results indicated that CDK8 was overexpressed in CESC, and the survival rate of patients in the CDK8 hypermethylation group was higher than that in the CDK8 hypomethylation group. In addition, CDK8 was associated with immune cell infiltration in tumor tissues. Overall, these findings provide more evidences for the relationship between CDK8 and patient's overall survival, which could provide insights into clinical diagnosis and prognosis prediction for CESC.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096332050241022102545","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth, and neurological functions, in conjunction with mediator complex subunits 12 (MED12), MED13, and cyclin C.Cyclin-dependent kinase 8 (CDK8) is a paracrine transcriptional regulator involved in regulating cellular stress response, growth and neurological functions，in conjunction with mediator complex subunit 12 (MED12), MED13 and cyclin C. Studying the relationship between CDK8 and cervical squamous cell carcinoma (CESC) has significant clinical implications in diagnosis, treatment, and prognosis. We analyzed the relationship between CDK8 and poor prognosis of CESC. The results indicated that CDK8 was overexpressed in CESC, and the survival rate of patients in the CDK8 hypermethylation group was higher than that in the CDK8 hypomethylation group. In addition, CDK8 was associated with immune cell infiltration in tumor tissues. Overall, these findings provide more evidences for the relationship between CDK8 and patient's overall survival, which could provide insights into clinical diagnosis and prognosis prediction for CESC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

CDK8作为预测宫颈鳞状细胞癌（CESC）总生存期的治疗靶点

细胞周期蛋白依赖性激酶8 （CDK8）是一种参与调节细胞应激反应、生长和神经功能的旁分泌转录调节剂，与介质复合物亚单位12 （MED12）、MED13和细胞周期蛋白c一起参与调节细胞应激反应、生长和神经功能。研究CDK8与宫颈鳞状细胞癌（CESC）的关系对诊断、治疗和预后具有重要的临床意义。我们分析CDK8与CESC预后不良的关系。结果表明，CDK8在CESC中过表达，CDK8高甲基化组患者的生存率高于CDK8低甲基化组患者。此外，CDK8与肿瘤组织中免疫细胞的浸润有关。综上所述，这些发现为CDK8与患者总生存的关系提供了更多的证据，可以为CESC的临床诊断和预后预测提供见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.